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Abstract
Natural killer (NK) cells are highly specialized effectors of the innate immune system that hold promise for adoptive cancer
immunotherapy. Their cell killing activity is primarily mediated by the pro-apoptotic serine protease granzyme B (GrB),
which enters targets cells with the help of the pore-forming protein perforin. We investigated expression of a chimeric GrB
fusion protein in NK cells as a means to augment their antitumoral activity. For selective targeting to tumor cells, we fused
the epidermal growth factor receptor (EGFR) peptide ligand transforming growth factor a (TGFa) to human pre-pro-GrB.
Established human NKL natural killer cells transduced with a lentiviral vector expressed this GrB-TGFa (GrB-T) molecule in
amounts comparable to endogenous wildtype GrB. Activation of the genetically modified NK cells by cognate target cells
resulted in the release of GrB-T together with endogenous granzymes and perforin, which augmented the effector cells’
natural cytotoxicity against NK-sensitive tumor cells. Likewise, GrB-T was released into the extracellular space upon
induction of degranulation with PMA and ionomycin. Secreted GrB-T fusion protein displayed specific binding to EGFR-
overexpressing tumor cells, enzymatic activity, and selective target cell killing in the presence of an endosomolytic activity.
Our data demonstrate that ectopic expression of a targeted GrB fusion protein in NK cells is feasible and can enhance
antitumoral activity of the effector cells.
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Introduction
Natural killer (NK) cells are highly specialized effectors of the
innate immune system. They play an important role in the defense
against viral infection and the elimination of neoplastic cells [1].
Natural cytotoxicity of NK cells can be triggered rapidly upon
appropriate stimulation, and is regulated by a complex balance of
signals from germline-encoded activating and inhibitory cell
surface receptors [2]. Following target cell recognition and
activation, lytic granules within the effector cells are polarized
towards the immunological synapse, where they fuse with the
plasma membrane and release their contents into the synaptic cleft
between effector and target cell [3,4]. Similar to cytotoxic T cells,
cell killing by NK cells is primarily mediated by the granzyme
family of serine proteases, and the pore-forming protein perforin
[5]. Thereby the pro-apoptotic granzyme B (GrB) plays the most
crucial role for cytotoxicity [6]. Initially, GrB is expressed as an
inactive precursor protein. This pre-pro-GrB carries an N-
terminal signal peptide, directing packaging of the protein into
secretory granules, followed by the activation dipeptide Gly-Glu.
Removal of this peptide by the cysteine protease cathepsin C
generates the enzymatically active form of GrB [7], which is stored
together with other granzymes and perforin in the dense core of
lytic granules. Upon release from cytotoxic lymphocytes, GrB
enters target cells in cooperation with perforin, and rapidly
induces apoptosis via caspase-dependent and caspase-independent
mechanisms [8].
Owing to the relatively small size of 227 amino acid residues for
mature GrB, its broad substrate specificity, and its ability to bypass
common apoptosis resistance mechanisms in tumor cells, GrB has
been employed as an effector molecule for the generation of
recombinant cell death-inducing fusion proteins [9,10]. Since GrB
is of human origin, such immunotoxin-like molecules are expected
to circumvent immunogenicity and other complications frequently
associated with recombinant toxins of plant or bacterial origin
[11]. Recombinant GrB and chimeric GrB fusion proteins that
harbor peptide ligands or antibody domains for tumor-specific cell
recognition have been successfully produced in bacterial, yeast and
mammalian expression systems [12,13,14,15,16,17], and have
been shown to retain potent cytotoxicity upon targeted delivery
into tumor cells [12,13,15,18,19,20].
Here, we investigated feasibility and consequences of expression
of a chimeric GrB fusion protein in human NK cells, utilizing
established NKL cells as a model. NK cells possess all pathways
required for processing, packaging, and triggered release of
endogenous wildtype GrB, which may be readily employed by
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targeting to tumor cells, we fused the epidermal growth factor
receptor (EGFR) peptide ligand transforming growth factor a
(TGFa) to human pre-pro-GrB. EGFR overexpression and
aberrant activation have been found in many tumors of epithelial
origin, and have been shown to contribute to malignant
transformation [21]. Due to its accessibility from the extracellular
space, EGFR constitutes an attractive target for therapeutic
antibodies and cytotoxic antibody or growth factor fusion proteins
[15,22,23,24]. NK cells transduced with a lentiviral vector
encoding the GrB-TGFa fusion protein expressed the chimeric
GrB-T molecule in amounts comparable to endogenous wildtype
GrB, which augmented natural cytotoxicity of the genetically
modified NK cells against NK-sensitive targets. Furthermore,
induction of degranulation resulted in the release of GrB-T from
vesicular compartments into the extracellular space. The secreted
fusion protein was functionally active, and displayed specific
binding to EGFR-overexpressing tumor cells as well as selective
target cell killing in the presence of an endosomolytic activity.
Results
Expression of the granzyme B-TGFa fusion protein GrB-T
in NK cells
cDNA encoding human pre-pro-GrB was fused via a flexible
(Gly4Ser)4-His6 linker to a sequence encoding the EGFR-specific
peptide ligand TGFa followed by C-terminal Myc and hexa-
histidine tags in the lentiviral transfer vector pSIEW, that also
encodes enhanced green fluorescent protein (EGFP) as a marker
(Fig. 1A). After generation of lentiviral particles and transduction
of human NKL cells, EGFP-expressing NKL/GrB-T cells were
enriched by two rounds of flow cytometric cell sorting. Likewise,
NKL/GrBS183A-T control cells were generated by lentiviral
transduction with a vector encoding a fusion of TGFa with the
enzymatically inactive GrB mutant GrBS183A [14]. In the enriched
NKL/GrB-T and NKL/GrBS183A-T cell populations, GrB-T and
GrBS183A-T mRNA expression was verified by semi-quantitative
RT-PCR analysis (Fig. 1B). GrB-T and GrBS183A-T proteins with
an apparent molecular mass of 40 kDa were readily detected in
addition to endogenous wildtype GrB by immunoblot analysis of
NKL cell lysates with GrB-specific antibody (Fig. 1C), confirming
expression and integrity of the fusion proteins. Intracellular
staining of NKL/GrB-T and NKL/GrBS183A-T cells with Myc-
tag-specific antibody also verified expression of GrB-T and
GrBS183A-T in transduced NKL cells (Fig. 1D).
Ectopic expression of GrB-T enhances natural cytotoxicity
of NKL cells
Total levels of GrB in parental and genetically modified NKL
cells were analyzed by intracellular staining. We observed a
marked increase in total GrB in NKL/GrB-T and NKL/
GrBS183A-T cells in comparison to unmodified NKL, attributed
to GrB-T and GrBS183A-T fusion proteins ectopically expressed in
addition to endogenous wildtype GrB (Fig. 2A, left panel). In
contrast, expression levels of perforin remained unchanged by
transduction with the lentiviral vectors, and were comparable in
NKL, NKL/GrB-T and NKL/GrBS183A-T cells (Fig. 2A, right
panel).
Next, we investigated natural cytotoxicity of NKL/GrB-T and
NKL/GrBS183A-T cells in FACS-based assays with NKL-sensitive
C1R-neo and Jurkat cells as targets. Parental NKL cells were
included for comparison. As expected, co-incubation of Jurkat and
C1R-neo cells with unmodified NKL cells for 4 h revealed
significant cell killing activity at different E/T ratios, which was
very similar for NKL/GrBS183A-T cells that express the enzymat-
ically inactive fusion protein (Fig. 2B, upper panels). In contrast,
natural cytotoxicity of NKL/GrB-T cells was markedly increased,
resulting in 70% lysis of C1R-neo cells at an E/T ratio of 20:1,
while cell killing by NKL/GrBS183A-T and parental NKL was 38
and 30% under these conditions. Also cytotoxicity of NKL/GrB-T
cells towards Jurkat cells was enhanced, albeit to a lower extent
(45% cell killing at an E/T ratio of 20:1 versus 29 and 33% cell
killing for NKL/GrBS183A-T and NKL, respectively).
Release of secretory granular proteins and perforin activity
require the presence of Ca
2+. When cell killing experiments with
C1R-neo target cells were performed in the presence of the Ca
2+
chelator EGTA, cytotoxicity of NKL/GrB-T, NKL/GrBS183A-T,
and NKL cells was abolished, indicating dependence of cell killing
on granule exocytosis and perforin (Fig. 2B, lower panel, left).
Figure 1. Expression of the granzyme B-TGFa fusion protein
GrB-T in NK cells. (A) Schematic representation of the lentiviral
transfer vector pS-GrB-T-IEW that encodes under the control of the
Spleen Focus Forming Virus promoter (SFFV) a fusion of human GrB
with TGFa, followed by an internal ribosome entry site (IRES) and cDNA
encoding enhanced green fluorescent protein (EGFP) as a marker. SP,
GrB signal peptide; DP, GrB activation dipeptide; GrB21–247, mature form
of GrB; L, flexible linker; M, Myc tag; H, hexa-histidine tag. The similar
transfer vector pS-GrBS183A-T-IEW encodes enzymatically inactive
mutant GrBS183A fused to TGFa (not shown). After transduction with
S-GrB-T-IEW or S-GrBS183A-T-IEW vector particles, EGFP-expressing NKL/
GrB-T and NKL/GrBS183A-T cells were enriched by flow cytometric cell
sorting, and analyzed for GrB-T expression. (B) GrB-T mRNA expression
in NKL/GrB-T and NKL/GrBS183A-T cells was verified by semi-quantitative
RT-PCR. (C) Expression of GrB-T proteins in NKL/GrB-T and NKL/GrBS183A-
T cells was investigated by immunoblot analysis of cell lysates with GrB-
specific antibody. c-Tubulin was analyzed as a loading control. (D)
Expression of GrB-T proteins in NKL/GrB-T and NKL/GrBS183A-T cells was
confirmed by intracellular staining with Myc-tag-specific antibody and
flow cytometry (open areas). In all experiments parental NKL cells
served as controls.
doi:10.1371/journal.pone.0061267.g001
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panel, right). This suggests that in the absence of the TGFa target
receptor, GrB-T fusion protein can act in a manner similar to
endogenous wildtype GrB and enhance natural cytotoxicity of
NKL cells upon encounter of NK-sensitive targets. For this
increased target cell killing, enzymatic activity of the GrB-T fusion
protein as well as intact granule exocytosis and perforin activity
were required.
Cytotoxicity of NKL/GrB-T cells towards EGFR-expressing
tumor cells
Next, we investigated whether NKL/GrB-T cells also display
enhanced cytotoxic activity against EGFR-expressing tumor cells
employing established human MDA-MB468 breast carcinoma
and A431 squamous cell carcinoma cells as targets. These cells
express high levels of EGFR on the cell surface as confirmed by
flow cytometry (Fig. 3A). Cell killing activity of NKL/GrB-T and
NKL/GrBS183A-T cells against MDA-MB468 and A431 cells was
assessed in FACS-based assays upon co-incubation of effector and
target cells for 4 h at different ratios. Parental NKL cells were
included for comparison (Fig. 3B). In contrast to Jurkat and C1R-
neo cells, at the tested E/T ratios EGFR-expressing MDA-MB468
and A431 cells were resistant to lysis by parental NKL cells as well
as the genetically modified derivatives NKL/GrB-T and NKL/
GrBS183A-T.
NK cell-mediated cytotoxicity requires efficient activation of the
effector cells upon recognition of target cells. To investigate
polarization of cytotoxic granules to the site of contact and release
of granular contents into the synaptic cleft, we performed confocal
laser scanning microscopy analysis with mixed cultures of NKL,
and NKL-sensitive or NKL-resistant cancer cells as targets.
Parental NKL or NKL/GrB-T cells were added to C1R-neo or
MDA-MB468 cells, and stained with perforin-specific antibody to
visualize cytotoxic granules and distinguish effector and target
cells. NK cells in the absence of targets were included for
comparison. In NK cells incubated for 1 h with C1R-neo,
perforin-containing granules were concentrated at the interface
with the target cells (Fig. 4A, middle panel), indicative of effector
cell activation. In contrast, upon incubation with MDA-MB468,
Figure 2. Natural cytotoxicity of NKL/GrB-T and NKL/GrBS183A-
T cells. (A) Total levels of GrB and perforin expressed by parental NKL
(dark gray areas), NKL/GrB-T (bold lines) and NKL/GrBS183A-T cells
(dotted lines) was analyzed by intracellular staining with GrB-specific
antibody (left) or perforin-specific antibody (right) and flow cytometry.
NKL cells incubated with isotype-matched antibodies served as controls
(light gray areas). (B) Cytotoxicity of NKL/GrB-T (filled squares) and NKL/
GrBS183A-T cells (open squares) towards C1R-neo and Jurkat cells was
determined in FACS-based cytotoxicity assays at different effector to
target ratios (E/T). Parental NKL cells (filled circles) were included for
comparison. Dependence of target cell killing on the release of granular
proteins was confirmed by incubating C1R-neo target cells with NKL
effector cells in the presence of 2 mM of the Ca
2+ chelator EGTA.
Representative data of one of three independent experiments are
shown. Absence of EGFR expression on the surface of C1R-neo and
Jurkat cells was confirmed by flow cytometry with EGFR-specific
antibody (open areas). Cells treated only with secondary antibody
served as controls (shaded areas).
doi:10.1371/journal.pone.0061267.g002
Figure 3. Cytotoxicity of NKL/GrB-T and NKL/GrBS183A-T cells
towards EGFR-expressing tumor cells. (A) Expression of EGFR on
the surface of MDA-MB468 breast carcinoma and A431 squamous cell
carcinoma cells was determined by flow cytometry with EGFR-specific
antibody (open areas). Cells treated only with secondary antibody
served as controls (shaded areas). (B) Cytotoxicity of NKL/GrB-T (filled
squares) and NKL/GrBS183A-T cells (open squares) towards MDA-MB468
and A431 cells was determined in FACS-based cytotoxicity assays at
different E/T ratios. Parental NKL cells (filled circles) were included for
comparison.
doi:10.1371/journal.pone.0061267.g003
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with the targets, but showed little or no polarization of cytotoxic
granules towards the site of contact (Fig. 4A, right panel). This
resembled the distribution pattern observed in unstimulated NKL
cultured without target cells (Fig. 4A, left panel). To assess
differences in effector cell activation by the cancer cells, we
subsequently analyzed activation-induced degranulation of NKL
and NKL/GrB-T cells upon contact with C1R-neo and MDA-
MB468. Cells were co-incubated at an E/T ratio of 1:1 for 5 h,
before surface expression of the lysosomal associated membrane
protein LAMP-1 (CD107a) was measured by flow cytometry. This
functional marker for CTL and NK cell activity resides in the
membrane of lytic granules, and is mobilized to the cell surface
following activation-induced granule exocytosis. While CD107a
levels were markedly increased on the surface of NKL and NKL/
GrB-T cells upon encounter of C1R-neo cells (Fig. 4B, upper
panel), only marginal changes in CD107a expression were
observed upon contact of the effector cells with MDA-MB468
target cells (Fig. 4B, lower panel).
Hence, while NKL and NKL/GrB-T cells formed conjugates
with the EGFR-expressing targets, this interaction did not induce
effector cell activation, degranulation and target cell killing.
Release of GrB-T protein from NKL/GrB-T cells upon
activation-induced degranulation
To facilitate release of GrB-T fusion protein from NKL cells for
functional analysis, NKL/GrB-T and NKL/GrBS183A-T cells
were stimulated with PMA and ionomycin, and induction of
degranulation was confirmed by demonstrating enhanced expres-
sion of CD107a on the cell surface (Fig. 5A). Enzymatic activity of
released proteins was analyzed using the GrB-specific peptide
substrate Ac-IETD-pNA (Fig. 5B). Thereby concentration-depen-
dent GrB activity was found in supernatant of activated parental
NKL cells. As expected, this was very similar for NKL/GrBS183A-
T cells that express enzymatically inactive fusion protein but also
harbor endogenous wildtype GrB. In contrast, markedly enhanced
GrB activity was detected in supernatant from activated NKL/
GrB-T, indicating release of enzymatically active GrB-T fusion
protein from these cells in addition to endogenous wildtype GrB.
Functionality of the TGFa domain of GrB-T was investigated in
cell binding experiments with EGFR-overexpressing MDA-
MB468 cells. As a control, human MDA-MB453 breast carcinoma
cells were included, which are negative for EGFR [20]. Tumor
cells were incubated with culture supernatants of activated NKL/
GrB-T and NKL/GrBS183A-T cells, and surface-bound proteins
were detected by flow cytometry with fluorochrome-labeled GrB-
specific antibody. For proteins from NKL/GrB-T and NKL/
GrBS183A-T cells, strong binding to the surface of MDA-MB468
cells, but not EGFR-negative MDA-MB453 cells was found
(Fig. 5C). Endogenous GrB released from parental NKL cells
displayed only marginal binding to MDA-MB468 and MDA-
MB453 cells.
These data show that GrB-T and GrBS183A-T fusion proteins
were indeed released from NKL cells upon activation-induced
degranulation. While GrB-T was bifunctional and displayed
enzymatic activity as well as EGFR-specific binding, the
GrBS183A-T control protein retained cell binding, but as expected
did not cleave GrB substrate.
Cytotoxic activity of GrB-T protein from activated NKL
cells
To analyze cytotoxic activity of GrB-T protein from NKL/
GrB-T cells, the cells were treated with PMA and ionomycin as
described above, cell-free supernatant was collected, and increas-
ing concentrations from 50 to 200 mg/mL of total granular
proteins were added to MDA-MB468 cells. Equal concentrations
of proteins released by NKL/GrBS183A-T and parental NKL cells
were included as controls. After 24 h, the relative number of viable
cells in comparison to target cells cultured in PMA- and
ionomycin-containing medium in the absence of NK cell proteins
was determined in WST-1 metabolization assays (Fig. 6A). A slight
reduction in cell viability was observed at high protein concen-
trations. However, this was independent from the source of the
granular proteins, and most likely due to the activity of
endogenous granzymes and perforin released by the different
NKL cell derivatives. To test whether insufficient intracellular
uptake of GrB-T protein was responsible for the lack of specific cell
killing, MDA-MB468 cells were treated with supernatant from
activated NKL/GrB-T cells, and uptake of GrB-T after 1.5 h at
37uC was analyzed by confocal laser scanning microscopy using
fluorochrome-conjugated GrB antibody. In the majority of target
cells, punctuate staining within the cytoplasm was found (Fig. 6B,
upper panel), suggesting receptor-mediated endocytosis of GrB-T
upon binding to EGFR and routing to endosome-like vesicular
structures. MDA-MB468 cells incubated with the same amount of
protein from activated parental NKL cells containing endogenous
wildtype GrB did not display intracellular staining with GrB-
specific antibody (Fig. 6B, lower panel).
To test whether release from endosomal vesicles in target cells
could facilitate access of GrB-T to cytosolic GrB substrates and
enable cytotoxic activity, next we treated target cells with
increasing concentrations of total granular proteins from activated
NKL/GrB-T cells in the presence of chloroquine. Indeed,
addition of the endosomolytic reagent strongly enhanced cytotox-
icity of GrB-T protein, resulting in effective and concentration-
dependent killing of target cells (Fig. 6C). Interestingly, chloro-
quine also increased cytotoxic activity of endogenous granular
proteins from NKL and NKL/GrBS183A-T cells. However, in
these cases much higher protein concentrations were required to
achieve significant cell killing.
Specificity of GrB-T-mediated cell killing
Apoptotic cell death is a hallmark of GrB-induced cytotoxicity.
To examine whether increased cell death observed upon treatment
with GrB-T was due to GrB-induced apoptosis, MDA-MB468
cells were incubated with supernatant from activated NKL/GrB-
T cells containing 100 mg/mL of total granular proteins in the
presence of chloroquine. Induction of apoptosis was measured by
determining the percentage of Annexin V and propidium iodide
double-positive cells. After 24 h, 34% of GrB-T-treated cells were
apoptotic, while treatment with granular proteins from NKL/
GrBS183A-T and parental NKL cells both resulted in 20% target
cell apoptosis (Fig. 7A).
Next, we investigated whether enhanced cytotoxicity of GrB-T
protein was dependent on EGFR expression on target cells.
EGFR-negative MDA-MB453 and EGFR-positive MDA-MB468
cells were each treated for 24 h with supernatant from activated
NKL/GrB-T cells containing 100 mg/mL of total granular
proteins in the presence of chloroquine, and effects on cell
viability were determined. As observed before, GrB-T-containing
supernatant was highly toxic for MDA-MB468 cells (Fig 7B, left
panel), while no significant reduction in viability was observed
upon treatment of MDA-MB453 cells (Fig 7B, right panel). To
confirm specificity of GrB-T-mediated cell killing, a similar
experiment was performed with MDA-MB468 cells pre-treated
with EGFR-specific antibody 425 [25]. While in the absence of
competitor GrB-T treatment resulted in 54% cell killing, blockade
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PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e61267of the ligand binding site of EGFR by the antagonistic antibody
abrogated GrB-T binding and reduced cytotoxicity to 30%, which
was similar to the levels observed for granular proteins from NKL
and NKL/GrBS183A-T cells (Fig. 7C).
The inability of mutant GrBS183A-T to enhance cell death
indicates that the enzymatic activity of the GrB domain is required
for specific cell killing by GrB-T. This was confirmed by pre-
treatment of GrB-T from activated NKL/GrB-T cells with the
GrB-specific peptide aldehyde inhibitor Ac-IETD-CHO, which
markedly reduced specific cytotoxicity (Fig. 7D). Specific binding
of GrB-T from NKL/GrB-T cells and high and selective
cytotoxicity in the presence of chloroquine was also observed for
other EGFR-overexpressing tumor cells such as A431, confirming
that these effects are not restricted to MDA-MB468 target cells
(Fig. 8).
Taken together, these data demonstrate that GrB-T released by
NK cells is bifunctional and selectively cytotoxic for EGFR-
overexpressing target cells. Cell killing by GrB-T required TGFa-
mediated binding to EGFR on the cell surface, release from
vesicular compartments in target cells, and subsequent cleavage of
intracellular GrB substrates.
Discussion
Significant progress has been made over the last decade towards
realizing the potential of natural killer cells for cancer immuno-
therapy [1,26]. NK cells can respond rapidly to transformed and
stressed cells, and have the intrinsic potential to extravasate and
reach their targets in almost all body tissues. In experimental
models, tumor-specificity of NK cells has been enhanced by
genetic modification for expression of chimeric antigen receptors
Figure 4. Conjugate formation and redistribution of cytotoxic granules upon target cell contact. (A) Parental NKL and NKL/GrB-T cells
were incubated with C1R-neo or MDA-MB468 target cells at an E/T ratio of 1:1 for 1 h at 37uC, stained with perforin-specific antibody as indicated
(red), and analyzed by confocal laser scanning microscopy. As a control, NK cells were incubated without target cells. Maximum projection of a z-stack
series is shown in each case. N: NK cell; T: target cell. (B) To assess activation of NK cells upon target cell contact, parental NKL and NKL/GrB-T cells
were incubated with C1R-neo (upper panel) or MDA-MB468 target cells (lower panel) at an E/T ratio of 1:1 for 5 h at 37uC, before analysis of cell
surface-associated degranulation marker CD107a by flow cytometry (open areas). NKL cells incubated in the absence of target cells served as controls
(shaded areas).
doi:10.1371/journal.pone.0061267.g004
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antibody-mediated recognition of a defined tumor cell surface
antigen [27,28,29,30,31]. Alternatively, antitumoral activity may
be augmented by providing NK cells with a targeted effector
molecule that is released upon NK cell activation in soluble form,
and can act in concert with endogenous natural cytotoxicity
mechanisms. As a first step in this direction, here we expressed a
chimeric granzyme B fusion protein in human NK cells that
carries the peptide ligand TGFa for targeting to EGFR, and
evaluated its effect on natural cytotoxicity and its cell killing
activity towards EGFR-expressing tumor cells.
We used established NKL cells as a model system [32]. These
cells display natural cytotoxicity and can mediate antibody-
dependent cell-mediated cytotoxicity (ADCC), but their overall
cytotoxic potential is moderate [33]. Transduction with a GrB-T-
encoding lentiviral vector resulted in the integration of the
provirus into the NKL cells’ genome (data not shown), and stable
long-term expression of the chimeric fusion protein at levels
comparable to endogenous wildtype GrB in these cells. To direct
ectopically expressed GrB-T to the lytic granules of the NK cells
and facilitate activation-triggered release, we employed complete
pre-pro-GrB as an effector domain. Consequently, the chimeric
fusion protein like wildtype GrB depends on removal of the signal
peptide and subsequent processing by cathepsin C to generate the
free N-terminus of mature GrB, that is required for enzymatic
activity [7,14]. Expression and granular storage of GrB-T resulted
in a marked increase in total intracellular GrB levels, while not
affecting the levels of other granular proteins like perforin.
NKL/GrB-T cells displayed significantly enhanced natural
cytotoxicity towards NK-sensitive target cells. This could be
attributed to the activity of GrB-T, since NKL/GrBS183A-T cells
that produce similar amounts of the enzymatically inactive fusion
protein only showed cell killing comparable to unmodified
parental NKL. Cytotoxicity of NKL/GrB-T cells was abrogated
by addition of EGTA, which chelates Ca
2+ essential for the release
of granular proteins and for perforin activity [34,35,36]. This
suggests that ectopically expressed GrB-T is released via the same
mechanism as endogenous wildtype GrB, and likely employs
perforin to gain access to GrB substrates in target cells. In contrast
to EGFR-negative leukemia and lymphoma cells, EGFR-overex-
pressing cancer cells of solid tumor origin were resistant to the
cytolytic activity of NKL cells. Unexpectedly, this was also the case
for NKL/GrB-T cells that express the EGFR-specific fusion
protein. This could be explained by insufficient activation of the
NK cells upon contact with the NKL-resistant targets. While
conjugates were formed between effector and MDA-MB468 target
cells, lytic granules were not re-oriented towards the site of contact,
and degranulation of NKL cells and release of granular proteins
into the immunological synapse was not induced. Hence, GrB-T
did not gain access to the target cells.
To facilitate release of GrB-T along with endogenous granular
proteins from vesicular compartments, we stimulated genetically
modified NKL cells with the phorbol ester PMA and the calcium
ionophore ionomycin [37,38]. Culture supernatant was collected
and used for subsequent analysis of the fusion protein. The
presence of GrB-T in supernatant and its functionality were
confirmed in cell binding experiments and enzymatic assays with a
synthetic GrB substrate. We observed strong and selective binding
of the fusion protein to EGFR-expressing tumor cells. Despite
efficient cell binding, however, GrB-T released from activated
NKL/GrB-T cells did not facilitate killing of EGFR-overexpress-
ing tumor cells in the absence of an exogenous endosomolytic
activity. Instead, we found the protein trapped in target cells
within intracellular vesicles, where it did not have access to its
cytosolic substrates.
Under physiological conditions, delivery of wildtype GrB into
the cytosol of target cells is aided by the pore-forming protein
perforin. This is accomplished either via formation of active
perforin pores directly in the cell membrane, or disruption of
vesicular membranes after co-endocytosis of GrB and perforin
[39,40,41]. Enhanced natural cytotoxicity of NKL/GrB-T cells
towards EGFR-negative targets suggests that GrB-T like wildtype
GrB can cooperate with perforin to enter cells and induce cell
death. The TGFa domain contributes approximately 6 kDa to the
molecular mass of GrB-T, which is well within the size limit
Figure 5. Release of GrB-T protein upon degranulation of NK
cells. (A) Degranulation of NKL, NKL/GrB-T and NKL/GrBS183A-T cells was
induced by treatment with PMA and ionomycin for 5 h at 37uC, and
culture supernatants were harvested. To confirm activation of cells,
CD107a expression was analyzed by flow cytometry (open areas).
Unstimulated cells served as controls (shaded areas). (B) To determine
enzymatic activity of GrB and GrB-T proteins, GrB-specific peptide
substrate Ac-IETD-pNA was incubated with 50 to 200 mg/mL of total
proteins from supernatants of activated NKL (filled circles), NKL/GrB-T
(filled squares) or NKL/GrBS183A-T cells (open squares). Substrate
cleavage was determined by measuring the absorbance at 405 nm.
Mean values 6 SEM are shown; n=4. *, P,0.05. (C) Binding of GrB-T
(bold line) and mutant GrBS183A-T protein (dotted line) released by
activated NKL/GrB-T and NKL/GrBS183A-T cells to EGFR-positive MDA-
MB468 and EGFR-negative MDA-MB453 breast carcinoma cells was
determined by flow cytometry with GrB-specific antibody. Cells treated
with medium (shaded areas) or proteins released by activated parental
NKL cells (regular line) served as controls.
doi:10.1371/journal.pone.0061267.g005
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conjugates with perforin [33]. Within the synaptic cleft between
fully activated effector cells and targets, high local perforin
concentrations can be expected. In contrast, the amount of
perforin in culture supernatants of PMA and ionomycin stimulated
NKL cells was below the detection limit of immunoblots, and may
not have supported cytosolic delivery of GrB-T.
However, when the endosomolytic reagent chloroquine was
present, GrB-T from NKL/GrB-T supernatant efficiently killed
EGFR-overexpressing tumor cells. Chloroquine is a weak base
that accumulates in acidic compartments such as late endosomes
and lysosomes, where it interferes with the pH equilibrium,
leading to osmotic rupture of the vesicles [42]. It has previously
been used to facilitate cytosolic delivery of recombinant GrB
fusion proteins and other targeted cell-death inducing proteins in
the absence of perforin [15,20,43]. Importantly, cell killing activity
of GrB-T in the presence of chloroquine was strictly dependent on
specific TGFa - EGFR interaction as well as enzymatic activity of
the GrB domain. Thereby viability of EGFR-overexpressing
breast carcinoma and squamous cell carcinoma cells was reduced
to about 50% at a concentration of 100 mg/mL of total granular
proteins from activated NKL/GrB-T cells, which corresponds to
approximately 5 to 10 ng/mL (125 to 250 pM) of GrB-T as
estimated in cytotoxicity assays employing recombinant GrB-T
expressed in yeast as a standard [15] (data not shown).
Our data demonstrate that ectopic expression of a targeted GrB
fusion protein can enhance antitumoral activity of NK cells. Upon
proper activation by target cells, the chimeric GrB-T molecule was
released, exhibiting functionality similar to wildtype GrB and
markedly enhancing natural cytotoxicity. In addition, the fusion
protein displayed EGFR-specific binding and the ability to kill
EGFR-expressing tumor cells specifically. Hence, NK cells
modified to express a targeted GrB derivative may become
therapeutically useful, if NK cell activation at the tumor site and
triggered release of the effector molecule can be ensured. This may
for example be achieved by co-expressing a targeted GrB fusion
protein together with a tumor-specific chimeric antigen receptor of
the same or different specificity, that can bypass natural
mechanisms preventing activation [31]. Experiments in this
direction have been initiated.
Materials and Methods
Cells and culture conditions
Human Jurkat acute T cell leukemia cells, C1R-neo B-cell
lymphoblastoid cells (both ATCC, Manassas, VA), and human
NKL natural killer cells [32] were maintained in RPMI 1640
medium (Lonza, Cologne, Germany). Human MDA-MB453 and
MDA-MB468 breast carcinoma cells, A431 squamous cell
carcinoma cells, and 293T cells (all ATCC) were cultured in
DMEM (Lonza). All media were supplemented with 10% heat-
inactivated FBS, 2 mM L-glutamine, 100 U/mL penicillin,
100 mg/mL streptomycin, in addition containing 1.8 mg/mL
G418 (C1R-neo), or 10% heat-inactivated horse serum and
200 IU/mL recombinant human IL-2 (Proleukin; Novartis
Pharma, Nu ¨rnberg, Germany) (NKL).
Lentiviral GrB-T expression constructs and transduction
of NKL cells
cDNA encoding a fusion of human pre-pro-GrB, linked via a
flexible peptide linker to human TGFa and C-terminal Myc and
His6 tags was assembled by stepwise PCR utilizing full-length GrB
cDNA [14] and plasmid pPIC9-GrB-T [15] as templates. The
GrB-TGFa (GrB-T) sequence was inserted into plasmid
pHR’SIN-cPPT-SIEW (pSIEW) [44] upstream of IRES and
EGFP sequences of the vector, resulting in the lentiviral transfer
plasmid pS-GrB-T-IEW which allows co-expression of GrB-T and
EGFP. Following a similar strategy, plasmid pS-GrBS183A-T-IEW
was generated that encodes the enzymatically inactive control
protein GrBS183A-T [15]. VSV-G pseudotyped lentiviral vector
particles were produced by co-transfecting 293T cells with the
respective lentiviral transfer plasmid together with packaging and
envelope plasmids pCMVDR8.91 and pMD2.G [45] using
standard calcium phosphate transfection. Culture supernatants
containing pseudotyped lentiviral vector particles were collected
Figure 6. Cytotoxic activity of proteins released by activated NK cells. (A) EGFR-positive MDA-MB468 cells were treated with increasing
concentrations of total proteins from supernatants of activated NKL (closed circles), NKL/GrB-T (closed squares), or NKL/GrBS183A-T cells (open
squares). After 24 h, the relative number of viable cells in comparison to medium-treated controls was determined in WST-1 assays. Mean values 6
SEM are shown; n=9. (B) To investigate uptake and intracellular localization of GrB-T protein, MDA-MB468 cells were treated with GrB-T-containing
supernatant from NKL/GrB-T cells for 60 min at 4uC, washed and incubated for another 90 min at 37uC, before staining with GrB-specific antibody
(red) and confocal laser scanning microscopy. Control cells were incubated with supernatant from activated parental NKL cells. Nuclei were stained
with DAPI (blue). Merged images are shown. (C) To facilitate release of internalized proteins from endosomes, MDA-MB468 were treated with total
proteins from supernatants of activated NKL, NKL/GrB-T, or NKL/GrBS183A-T cells in the presence of 25 mM of the endosomolytic reagent chloroquine,
and the relative number of viable cells in comparison to controls treated with chloroquine-containing medium was determined in WST-1 assays.
Mean values 6 SEM are shown; n=9. ***, P,0.001; **, P,0.01.
doi:10.1371/journal.pone.0061267.g006
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transduction, lentiviral particle-containing supernatants were
added to NKL cells in the presence of 8 mg/mL polybrene, and
the mixtures were centrifuged for 90 min at 32uC and 1,8006g.
Then, the cells were cultured overnight at 37uC before replacing
the medium. After 48 h, cells were analyzed for EGFP expression
by direct flow cytometry using FACSCalibur or FACSCanto II
flow cytometers (BD Biosciences, Heidelberg, Germany) and
CELLQuest Pro or FACSDiva software (BD Biosciences).
Homogeneous pools of EGFP-expressing NKL cells were obtained
by two rounds of sorting using a FACSAria fluorescence-activated
cell sorter (BD Biosciences).
Analysis of GrB and perforin expression
Expression of GrB-T and GrBS183A-T mRNA was analyzed by
semi-quantitative RT-PCR using total RNA from NKL/GrB-T,
NKL/GrBS183A-T, or parental NKL cells as templates, and
oligonucleotide primers 5’-SacII-GrB (5’-CGGCCCGCGGAC-
CATGCAACCAATCCTGCTTCTGCTGGCCTTCC-39) and
3’-His-SacII (5’-CTACCGCGGCTAGTGATGGTGAT-
GATGGTGATTCAGATCCTC-3’). For immunoblot analysis,
NKL/GrB-T, NKL/GrBS183A-T, and parental NKL cells were
cultured in the presence of GolgiStop
TM (BD Biosciences) for 5 h
at 37uC. Cells were collected by centrifugation, and lysed by
sonication at 4uC in buffer containing 20 mM Tris-HCl, pH 7.5,
150 mM NaCl, 2 mM EDTA, 1% sodium deoxycholate, 1%
Triton X-100, 0.25% SDS (all Roth, Karlsruhe, Germany), 1 mM
PMSF, 1 mM sodium orthovanadate (Sigma-Aldrich, Tauf-
kirchen, Germany), and protease inhibitor cocktail (Roche
Diagnostics, Mannheim, Germany). Subsequently, cleared cell
extracts were subjected to SDS-PAGE and immunoblot analysis
with GrB-specific antibody 2C5 (Santa Cruz Biotechnology,
Heidelberg, Germany), followed by HRP-conjugated secondary
antibody and chemiluminescent detection. As a loading control,
Figure 7. Selective cytotoxicity of GrB-T fusion protein. (A)
Induction of apoptosis after treatment of MDA-MB468 cells for 24 h
with 100 mg/mL of total proteins from supernatants of activated NKL,
NKL/GrB-T, or NKL/GrBS183A-T cells in the presence of 25 mM chloro-
quine was analyzed by determining the percentage of Annexin V and
propidium iodide (PI) double-positive cells by flow cytometry. (B) EGFR-
positive MDA-MB468 (left) and EGFR-negative MDA-MB453 cells (right)
were treated with 100 mg/mL of total proteins from supernatants of
activated NKL, NKL/GrB-T, or NKL/GrBS183A-T cells in the presence of
25 mM chloroquine as indicated. Controls cells were treated with
medium containing PMA, ionomycin and chloroquine. After 24 h, the
relative number of viable cells was determined in WST-1 assays. (C) To
confirm specificity of cell killing, MDA-MB468 cells were pre-incubated
with 50 mg/mL of EGFR-specific antibody 425 as a competitor prior to
addition of proteins from NK cell supernatants and determination of
cytotoxicity as described in (B). Control cells were pre-incubated with
isotype-matched control antibody. (D) Dependence of cell killing on GrB
activity was confirmed by pre-incubation of culture supernatants from
activated NKL cells with 400 mM of GrB-specific peptide aldehyde
inhibitor Ac-IETD-CHO before addition to MDA-MB468 cells and
determination of cytotoxicity as described in (B). In all cases mean
values 6 SEM are shown; n=3 (A); n=6 (B–D). ***, P,0.001; **, P,0.01;
*, P,0.05; ns, P.0.05.
doi:10.1371/journal.pone.0061267.g007
Figure 8. Cell binding and cytotoxicity of GrB-T fusion protein
towards A431 cells. (A) Binding of GrB-T (bold line) and mutant
GrBS183A-T protein (dotted line) released by activated NKL/GrB-T and
NKL/GrBS183A-T cells to EGFR-positive A431 squamous cell carcinoma
cells was determined by flow cytometry with GrB-specific antibody.
Cells treated with medium (shaded areas) or proteins released by
activated parental NKL cells (regular line) served as controls. (B) To
determine cytotoxicity, A431 cells were treated with 100 mg/mL of total
proteins from supernatants of activated NKL, NKL/GrB-T, or NKL/
GrBS183A-T cells in the presence of 100 mM chloroquine as indicated.
Controls cells were treated with medium containing PMA, ionomycin
and chloroquine. After 24 h, the relative number of viable cells was
determined in WST-1 assays. Mean values 6 SEM are shown; n=3. **,
P,0.01; *, P,0.05; ns, P.0.05.
doi:10.1371/journal.pone.0061267.g008
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(Sigma-Aldrich).
For intracellular staining, up to 1610
6 NKL/GrB-T, NKL/
GrBS183A-T, or parental NKL cells were cultured in the presence
of GolgiStop
TM for 5 h at 37uC, collected by centrifugation,
washed once with DPBS, and fixed and permeabilized by adding
200 mL of BD Cytofix/Cytoperm
TM solution (BD Biosciences) for
30 min at room temperature. Then, cells were washed twice with
BD Perm/Wash
TM buffer (BD Biosciences), and incubated with
either Alexa Fluor 647-conjugated Myc-tag-specific antibody 9E10
(Santa Cruz Biotechnology) for detection of GrB-T and GrBS183A-
T fusion proteins, Alexa Fluor 647-conjugated human GrB-
specific antibody GB11 (BD Biosciences) for analysis of total GrB
levels, or phycoerythrin-conjugated perforin-specific antibody dG9
(BD Biosciences) for analysis of total perforin levels. Subsequently,
cells were analyzed using a FACSCalibur flow cytometer and
CELLQuest Pro software.
Cytotoxicity assay
Cytotoxic activity of NKL effector cells towards target cells was
analyzed in FACS-based assays as described [31]. Briefly, target
cells were labeled with calcein violet AM (Molecular Probes,
Invitrogen, Karlsruhe, Germany), washed, and then co-cultured
with effector cells at various effector to target (E/T) ratios for 4-6 h
at 37uC. After co-culture, cells were centrifuged, and 200 mLo fa1
mg/mL propidium iodide (PI) solution were added to each sample
shortly before flow cytometric analysis with a FACSCanto II flow
cytometer. Specific cytotoxicity was calculated using FACSDiva
software. Dead target cells were determined as calcein violet AM
and PI double positive. Spontaneous target cell lysis was analyzed
in samples containing only labeled target cells, and subtracted to
obtain specific cell killing.
Degranulation of NKL cells
Activation of NKL cells and induction of degranulation was
investigated by analyzing surface expression of lysosomal-associ-
ated membrane protein LAMP-1 (CD107a) using BD FastImmu-
ne
TM CD107a APC detection antibody (BD Biosciences) accord-
ing to the manufacturer’s instructions. Briefly, NKL cells (1610
6
cells/mL) were either mixed with target cells at an E/T ratio of
1:1, or stimulated with 1 mg/mL phorbol 12-myristate 13-acetate
(PMA) and 1 mg/mL ionomycin (both Sigma-Aldrich) for 60 min
at 37uC in the presence of 5 mL of anti-CD107a-APC antibody.
Then, 1 mL of GolgiStop
TM was added to each sample, followed
by incubation for another 4 h at 37uC. Cells were washed, and
CD107a expression was analyzed using a FACSCalibur cytometer
and CellQuestPro software. To collect proteins released from
cytotoxic granules, NKL cells (up to 5610
6 cells/mL) were
stimulated with 1 mg/mL each of PMA and ionomycin for 6 h at
37uC in serum-free RPMI 1640 medium supplemented with
2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL strepto-
mycin, and 200 IU/mL IL-2. Culture supernatants were collected
and sterile filtered to remove cell debris before subsequent analysis.
Yields of total granular proteins from 5610
6 cells were typically in
the range of 200 to 750 mg.
GrB activity assay
Enzymatic activity of GrB proteins in supernatants from
activated NKL cells was analyzed using the synthetic GrB
substrate Ac-IETD-pNA (Alexis, Gru ¨nberg, Germany) as de-
scribed [20]. Cleavage reactions were prepared in duplicates with
reaction buffer (10 mM Hepes pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2) and 200 mM Ac-IETD-pNA in a total volume of 150 mL
per sample in 96-well plates. Samples were incubated for 20 h at
37uC, and substrate cleavage was quantified by measuring the
absorbance (A) at 405 nm (corrected for background by subtract-
ing A490) with a microplate reader (Molecular Devices, Ismaning,
Germany). Peptide substrate incubated in reaction buffer without
granular proteins served as blank.
Binding analysis
To examine EGFR surface expression, target cells (5610
5) were
incubated with anti-human EGFR antibody R1 (Santa Cruz
Biotechnology) for 60 min at 4uC, followed by APC-conjugated
goat anti-mouse secondary antibody (Jackson ImmunoResearch,
West Grove, PA, USA), and analysis with a FACSCalibur flow
cytometer and CELLQuest Pro software. To determine cell
binding of GrB-T and GrBS183A-T expressed in NK cells, target
cells (5610
5) were incubated with up to 50 mg of total granular
proteins from activated NKL cells for 60 min at 4uC. Unbound
proteins were removed, cells were washed, and bound GrB fusion
proteins were detected with Alexa Fluor 647-conjugated anti-
human GrB antibody GB11 by flow cytometry as described above.
Cell viability and apoptosis assays
Cytotoxic activity of GrB fusion proteins from NKL cell
supernatants was analyzed in WST-1 cell viability assays (Roche
Diagnostics) following the manufacturer’s recommendations.
Target cells were seeded in 96-well plates at a density of
122610
4 cells/well in triplicates, and incubated for 24 h at
37uC with 50 to 200 mg/mL of total granular proteins from
supernatants of activated NKL cells in the presence or absence of
25 mM chloroquine. After addition of WST-1 reagent for 4 h, the
relative number of viable cells in comparison to medium-treated
control cells was determined by measuring the absorbance (A) at
450 nm (corrected for background by subtracting A690). To
compete binding of GrB-T and GrBS183A-T to EGFR, target cells
were pre-incubated with 50 mg/mL of anti-EGFR antibody 425
[25] or an isotype-matched control antibody for 30 min at 4uC
prior to the addition of NKL cell supernatant and analysis of
cytotoxicity. Dependence of cytotoxic activity on the enzymatic
activity of GrB was confirmed by pre-incubation of total granular
proteins from supernatants of activated NKL cells with 400 mMo f
GrB-specific peptide aldehyde inhibitor Ac-IETD-CHO (Alexis)
for 30 min at room temperature before addition to target cells and
analysis of cytotoxicity. To determine induction of apoptosis,
target cells were seeded in 24-well plates at a density of 2610
5
cells/well, and incubated for 24 h at 37uC with 100 mg/mL of
total granular proteins from supernatants of activated NKL cells in
the presence of 25 mM chloroquine. Control cells were treated
with chloroquine-containing medium. For each sample, adherent
cells were detached with trypsin-EDTA and combined with cells
floating in the culture medium. Harvested cells were washed with
PBS, and labeled with Annexin V-APC and PI using the Annexin
V Apoptosis Detection Kit (eBiosciences, Frankfurt, Germany)
according to the manufacturer’s instructions. Fluorescence of cells
was measured with a FACSCanto II flow cytometer, and the
percentage of apoptotic and dead cells was calculated using
FACSDiva software.
Confocal laser scanning microscopy
To investigate conjugate formation and activation of NKL cells
upon target cell recognition, NKL cells were mixed with target
cells (E/T ratio of 1:1), and adhered to glass slides coated with
poly-L-lysine (Sigma-Aldrich). After co-incubation for 60 min at
37uC, cells were washed, fixed with 4% paraformaldehyde in PBS
for 20 min at room temperature, and permeabilized and blocked
for 60 min in buffer containing 0.1% Triton X-100, 3% BSA in
Expression of EGFR-Targeted Granzyme B in NK Cells
PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e61267PBS. Then cells were incubated with anti-human perforin
antibody dG9, followed by Alexa Fluor 546-conjugated anti-
mouse IgG (Molecular Probes). Cells were washed twice with PBS,
and analyzed with a Leica CTR 6500 laser scanning microscope
(Leica Microsystems, Bensheim, Germany). For analysis of uptake
of GrB-T fusion protein, MDA-MB468 target cells were grown
overnight on coverslips, and then treated for 60 min at 4uC with
supernatant of activated NKL/GrB-T or parental NKL cells
containing 200 mg/mL of total granular proteins. Then cells were
washed, and incubated for another 90 min at 37uC in fresh culture
medium to initiate uptake of GrB-T. Cells were fixed with 4%
paraformaldehyde in PBS for 20 min at room temperature,
permeabilized, and blocked for 60 min in buffer containing 0.1%
Triton X-100, 3% BSA in PBS. This was followed by incubation
of the cells with 2 mg/mL Alexa Fluor 647-conjugated anti-human
GrB antibody GB11 in 3% BSA in PBS for detection of GrB-T.
Nucleic acids were counterstained with DAPI. Cells were washed
twice with PBS, and analyzed with a Leica CTR 6500 laser
scanning microscope.
Statistical analysis
Differences between values were evaluated using the two-tailed
unpaired Student’s t test. P values ,0.05 were considered
significant. Statistical calculations were done using Prism 5
software (GraphPad Software, La Jolla, CA).
Acknowledgments
The authors thank Martin Zo ¨rnig and Christiane Sahm for helpful
suggestions and discussions, Manuel Grez for providing lentiviral vectors
and packaging constructs, and Tefik Merovci for help with flow cytometric
cell sorting (all Georg-Speyer-Haus).
Author Contributions
Conceived and designed the experiments: PO RAJ HBM WSW.
Performed the experiments: PO RAJ HBM. Analyzed the data: PO RAJ
WSW. Wrote the paper: PO RAJ WSW.
References
1. Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-
killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2: 850–861.
2. Lanier LL (2008) Up on the tightrope: natural killer cell activation and
inhibition. Nat Immunol 9: 495–502.
3. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, et al. (2001)
The immunological synapse. Annu Rev Immunol 19: 375–396.
4. Huse M, Quann EJ, Davis MM (2008) Shouts, whispers and the kiss of death:
directional secretion in T cells. Nat Immunol 9: 1105–1111.
5. Cullen SP, Brunet M, Martin SJ (2010) Granzymes in cancer and immunity.
Cell Death Differ 17: 616–623.
6. Chowdhury D, Lieberman J (2008) Death by a thousand cuts: granzyme
pathways of programmed cell death. Annu Rev Immunol 26: 389–420.
7. Pham CT, Ley TJ (1999) Dipeptidyl peptidase I is required for the processing
and activation of granzymes A and B in vivo. Proc Natl Acad Sci U S A 96:
8627–8632.
8. Afonina IS, Cullen SP, Martin SJ (2010) Cytotoxic and non-cytotoxic roles of the
CTL/NK protease granzyme B. Immunol Rev 235: 105–116.
9. Rosenblum MG, Barth S (2009) Development of novel, highly cytotoxic fusion
constructs containing granzyme B: unique mechanisms and functions. Curr
Pharm Des 15: 2676–2692.
10. Kurschus FC, Jenne DE (2010) Delivery and therapeutic potential of human
granzyme B. Immunol Rev 235: 159–171.
11. von Minckwitz G, Harder S, Ho ¨velmann S, Ja ¨ger E, Al-Batran SE, et al. (2005)
Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA
specific for the ErbB2/HER2 receptor in patients with advanced solid
malignomas. Breast Cancer Res 7: R617–R626.
12. Liu Y, Cheung LH, Hittelman WN, Rosenblum MG (2003) Targeted delivery of
human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel
class of recombinant highly cytotoxic agents. Mol Cancer Ther 2: 1341–1350.
13. Kurschus FC, Kleinschmidt M, Fellows E, Dornmair K, Rudolph R, et al.
(2004) Killing of target cells by redirected granzyme B in the absence of perforin.
FEBS Lett 562: 87–92.
14. Giesu ¨bel U, Da ¨lken B, Mahmud H, Wels WS (2006) Cell binding,
internalization and cytotoxic activity of human granzyme B expressed in the
yeast Pichia pastoris. Biochem J 394: 563–573.
15. Da ¨lken B, Giesu ¨bel U, Knauer SK, Wels WS (2006) Targeted induction of
apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth
factor domains for cell recognition. Cell Death Differ 13: 576–585.
16. Da ¨lken B, Jabulowsky RA, Oberoi P, Benhar I, Wels WS (2010) Maltose-
binding protein enhances secretion of recombinant human granzyme B
accompanied by in vivo processing of a precursor MBP fusion protein. PLoS
One 5: e14404.
17. Gehrmann M, Doss BT, Wagner M, Zettlitz KA, Kontermann RE, et al. (2011)
A novel expression and purification system for the production of enzymatic and
biologically active human granzyme B. J Immunol Methods 371: 8–17.
18. Liu Y, Zhang W, Niu T, Cheung LH, Munshi A, et al. (2006) Targeted
apoptosis activation with GrB/scFvMEL modulates melanoma growth,
metastatic spread, chemosensitivity, and radiosensitivity. Neoplasia 8: 125–135.
19. Stahnke B, Thepen T, Sto ¨cker M, Rosinke R, Jost E, et al. (2008) Granzyme B-
H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of
monocytic subtypes. Mol Cancer Ther 7: 2924–2932.
20. Jabulowsky RA, Oberoi P, Ba ¨hr-Mahmud H, Da ¨lken B, Wels WS (2012)
Surface charge-modification prevents sequestration and enhances tumor-cell
specificity of a recombinant granzyme B-TGFalpha fusion protein. Bioconjug
Chem 23: 1567–1576.
21. Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in
cancer. Curr Opin Cell Biol 21: 177–184.
22. Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer
therapy. Oncogene 19: 6550–6565.
23. Groner B, Hartmann C, Wels W (2004) Therapeutic antibodies. Curr Mol Med
4: 539–547.
24. Wels W, Biburger M, Mu ¨ller T, Da ¨lken B, Giesu ¨bel U, et al. (2004)
Recombinant immunotoxins and retargeted killer cells: employing engineered
antibody fragments for tumor-specific targeting of cytotoxic effectors. Cancer
Immunol Immunother 53: 217–226.
25. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, et al. (1987) Binding of an
antagonistic monoclonal antibody to an intact and fragmented EGF-receptor
polypeptide. Arch Biochem Biophys 252: 549–560.
26. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L (2008) Natural killer
cell-directed therapies: moving from unexpected results to successful strategies.
Nat Immunol 9: 486–494.
27. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, et al. (2002) Retargeting of
natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in
efficient and selective tumor cell destruction. Blood 100: 1265–1273.
28. Imai C, Iwamoto S, Campana D (2005) Genetic modification of primary natural
killer cells overcomes inhibitory signals and induces specific killing of leukemic
cells. Blood 106: 376–383.
29. Mu ¨ller T, Uherek C, Maki G, Chow KU, Schimpf A, et al. (2008) Expression of
a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK
cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer
Immunol Immunother 57: 411–423.
30. Pegram HJ, Jackson JT, Smyth MJ, Kershaw MH, Darcy PK (2008) Adoptive
transfer of gene-modified primary NK cells can specifically inhibit tumor
progression in vivo. J Immunol 181: 3449–3455.
31. Sahm C, Scho ¨nfeld K, Wels WS (2012) Expression of IL-15 in NK cells results in
rapid enrichment and selective cytotoxicity of gene-modified effectors that carry
a tumor-specific antigen receptor. Cancer Immunol Immunother 61: 1451–
1461.
32. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, et al. (1996)
Characterization of a cell line, NKL, derived from an aggressive human natural
killer cell leukemia. Exp Hematol 24: 406–415.
33. Kurschus FC, Fellows E, Stegmann E, Jenne DE (2008) Granzyme B delivery
via perforin is restricted by size, but not by heparan sulfate-dependent
endocytosis. Proc Natl Acad Sci U S A 105: 13799–13804.
34. Henkart PA, Millard PJ, Reynolds CW, Henkart MP (1984) Cytolytic activity of
purified cytoplasmic granules from cytotoxic rat large granular lymphocyte
tumors. J Exp Med 160: 75–93.
35. Ishiura S, Matsuda K, Koizumi H, Tsukahara T, Arahata K, et al. (1990)
Calcium is essential for both the membrane binding and lytic activity of pore-
forming protein (perforin) from cytotoxic T-lymphocyte. Mol Immunol 27: 803–
807.
36. Voskoboinik I, Thia MC, Fletcher J, Ciccone A, Browne K, et al. (2005)
Calcium-dependent plasma membrane binding and cell lysis by perforin are
mediated through its C2 domain: A critical role for aspartate residues 429, 435,
483, and 485 but not 491. J Biol Chem 280: 8426–8434.
37. Chatila T, Silverman L, Miller R, Geha R (1989) Mechanisms of T cell
activation by the calcium ionophore ionomycin. J Immunol 143: 1283–1289.
38. Morgan AJ, Jacob R (1994) Ionomycin enhances Ca2+ influx by stimulating
store-regulated cation entry and not by a direct action at the plasma membrane.
Biochem J 300: 665–672.
Expression of EGFR-Targeted Granzyme B in NK Cells
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e6126739. Froelich CJ, Orth K, Turbov J, Seth P, Gottlieb R, et al. (1996) New paradigm
for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize
granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and
subsequent apoptosis. J Biol Chem 271: 29073–29079.
40. Trapani JA, Smyth MJ (2002) Functional significance of the perforin/granzyme
cell death pathway. Nat Rev Immunol 2: 735–747.
41. Stewart SE, D’Angelo ME, Bird PI (2012) Intercellular communication via the
endo-lysosomal system: translocation of granzymes through membrane barriers.
Biochim Biophys Acta 1824: 59–67.
42. Zenke M, Steinlein P, Wagner E, Cotten M, Beug H, et al. (1990) Receptor-
mediated endocytosis of transferrin-polycation conjugates: an efficient way to
introduce DNA into hematopoietic cells. Proc Natl Acad Sci U S A 87: 3655–
3659.
43. Mahmud H, Da ¨lken B, Wels WS (2009) Induction of programmed cell death in
ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing
factor. Mol Cancer Ther 8: 1526–1535.
44. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, et al. (2002) High-
level transduction and gene expression in hematopoietic repopulating cells using
a human immunodeficiency virus type 1-based lentiviral vector containing an
internal spleen focus forming virus promoter. Hum Gene Ther 13: 803–813.
45. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D (1997) Multiply attenuated
lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871–
875.
Expression of EGFR-Targeted Granzyme B in NK Cells
PLOS ONE | www.plosone.org 11 April 2013 | Volume 8 | Issue 4 | e61267